XML 58 R30.htm IDEA: XBRL DOCUMENT v3.22.4

Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Sales revenue, net | Incyte Corporation (Incyte)
Concentration Risk [Line Items]
Percentage of significant accounts receivable	26.00%	31.00%	47.00%
Sales revenue, net | Janssen Biotech Inc.
Concentration Risk [Line Items]
Percentage of significant accounts receivable			19.00%
Sales revenue, net | Zai Lab Limited (Zai Lab)
Concentration Risk [Line Items]
Percentage of significant accounts receivable	15.00%	30.00%	11.00%
Sales revenue, net | Les Laboratoires Servier And Institut De Recherches Servier (Servier)
Concentration Risk [Line Items]
Percentage of significant accounts receivable	43.00%
Sales revenue, net | I-Mab Biopharma
Concentration Risk [Line Items]
Percentage of significant accounts receivable		16.00%
Accounts receivable | Provention Bio, Inc. (Provention)
Concentration Risk [Line Items]
Percentage of significant accounts receivable	84.00%
Accounts receivable | Zai Lab
Concentration Risk [Line Items]
Percentage of significant accounts receivable		23.00%
Accounts receivable | Imab
Concentration Risk [Line Items]
Percentage of significant accounts receivable		12.00%
Accounts receivable | McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC
Concentration Risk [Line Items]
Percentage of significant accounts receivable		18.00%
Accounts receivable | ASD Healthcare and Oncology Supply
Concentration Risk [Line Items]
Percentage of significant accounts receivable		18.00%

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ConcentrationRiskLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_IncyteCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_IMabBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ProventionBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ZaiLabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ImabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: